College of Food Science and Engineering, Ocean University of China, Qingdao 266003, China.
Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266237, China.
ACS Synth Biol. 2021 Mar 19;10(3):447-458. doi: 10.1021/acssynbio.0c00645. Epub 2021 Mar 9.
Human milk oligosaccharide (HMO) is a key component of human milk carbohydrates and is closely related to the nutrition and health benefits of breastfeeding in infants. 2'-Fucosyllactose (2'-FL) is the most abundant fucosylated HMO, which has remarkable value in nutrition and medicine, such as suppressing pathogen infection, regulating intestinal flora, and boosting immunity. However, 2'-FL production via the method of extraction or chemical synthesis cannot meet its large demand, and as a result, environmentally friendly and efficient biotechnological approaches, including enzymatic synthesis and microbial cell factory production, have been developed and applied to its commercialized production. This review introduces, summarizes, and discusses the recent advances in the biotechnological production of 2'-FL. Furthermore, future research directions for the biotechnological production of 2'-FL as well as the strategies to further improve its concentration are highlighted and discussed.
人乳寡糖（HMO）是母乳碳水化合物的关键组成部分，与人乳喂养对婴儿的营养和健康益处密切相关。2'-岩藻糖基乳糖（2'-FL）是最丰富的岩藻糖基 HMO，在营养和医学方面具有显著价值，如抑制病原体感染、调节肠道菌群和增强免疫力。然而，通过提取或化学合成的方法生产 2'-FL 无法满足其大量需求，因此，已经开发并应用了环保且高效的生物技术方法，包括酶合成和微生物细胞工厂生产，以实现其商业化生产。本综述介绍、总结和讨论了 2'-FL 生物技术生产的最新进展。此外，还强调并讨论了 2'-FL 生物技术生产的未来研究方向以及进一步提高其浓度的策略。
